COVID-19 vaccine candidates secure funds; Lysol gets EPA nod

AP,
Moderna
FILE - In this March 16, 2020, file photo, Neal Browning receives a shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. The first experimental COVID-19 vaccine in the U.S. is on track to begin a huge study next month to prove if it really can fend off the coronavirus, its manufacturer announced Thursday, June 11 -- a long-awaited step in the global vaccine race. The vaccine, developed by the U.S. National Institutes of Health and Moderna Inc., will be tested in 30,000 volunteers -- some given the real shot and some a dummy shot. (AP Photo/Ted S. Warren, File)

THE ASSOCIATED PRESS – Novavax has received $1.6 billion from the federal government to complete late-stage clinical development; establish large-scale manufacturing; and deliver 100 million doses of NVX-CoV2373, its COVID-19 vaccine candidate, as early as late 2020.

Regeneron Pharmaceuticals has received $450 million through Operation Warp Speed to make and supply its COVID-19 vaccine candidate, REGN-COV2.

The Environmental Protection Agency is starting to approve surface disinfectant products tested on the virus.

The agency said that it’s approved two products, Lysol Disinfectant Spray and Lysol Disinfectant Max Cover Mist, based on laboratory testing that shows the products are effective against SARS-CoV-2.

The Hartford is extending its COVID-19 personal auto payback plan through June.

Categories: Coronavirus, News, US & World News
Tags: , , , , ,

Related